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SUMMARY
Many psychiatric and neurological disorders are characterized by learning and memory deficits,
for which cognitive enhancement is considered a valid treatment strategy. The N-methyl-D-
aspartate receptor (NMDAR) is a prime target for the development of cognitive enhancers due to
its fundamental role in learning and memory. In particular, the NMDAR subunit NR2B improves
synaptic plasticity and memory when over-expressed in neurons. However, NR2B regulation is
not well understood and no therapies potentiating NMDAR function have been developed. Here,
we show that serine 1116 of NR2B is phosphorylated by cyclin-dependent kinase 5 (Cdk5). Cdk5-
dependent NR2B phosphorylation is regulated by neuronal activity and controls the receptor’s cell
surface expression. Disrupting NR2B-Cdk5 interaction using a small interfering peptide (siP)
increases NR2B surface levels, facilitates synaptic transmission, and improves memory formation
*To whom correspondence should be addressed. james.bibb@utsouthwestern.edu.
#Contributed equally
AUTHOR CONTRIBUTIONS
F.P., A.H., T.M.K., K.P., A.N., T.W., Z.Y. and J.A.B. designed experiments; F.P., A.H., T.M.K., K.P., P.Z., E.Y.Y., A.H.H., S.F.C.,
A.N. and A.G. performed and analyzed experiments; F.P., Z.Y. and J.A.B. supervised and interpreted experiments; F.P. and J.A.B.
wrote manuscript.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Neuron. Author manuscript; available in PMC 2015 March 05.
Published in final edited form as:
Neuron. 2014 March 5; 81(5): 1070–1083. doi:10.1016/j.neuron.2014.01.022.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
in vivo. Our results reveal a novel regulatory mechanism critical to NR2B function that can be
targeted for the development of cognitive enhancers.
INTRODUCTION
N-methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors that exhibit
broad expression within the nervous system and are critically involved in neuronal processes
such as synaptic plasticity and learning & memory (Bliss and Collingridge, 1993; Martin et
al., 2000). Functional NMDARs are obligate heterotetrameric complexes formed by two
glycine-binding GluN1 subunits assembled with two of several isoforms of the glutamate-
binding GluN2 (A, B, C or D subtypes) or glycine-binding GluN3 (A or B subtypes) (Cull-
Candy and Leszkiewicz, 2004; Dingledine et al., 1999). The biophysical properties of
NMDARs are dependent on their subunit composition (Morrisett, 1997). Indeed, NMDAR
subunit composition varies greatly between different synapses and neurons, as well as
during neuronal development (Monyer et al., 1994; Sheng et al., 1994). Therefore, precise
spatio-temporal regulation of NMDAR subunit expression, composition, trafficking and
localization is critical for proper neuronal function.
Brain regions involved in mnemonic functions rely predominantly upon GluN2A (NR2A)
and GluN2B (NR2B) subunit-containing NMDARs. During postnatal development, NR2B
expression steadily decreases, while NR2A levels rise. Compared to NR2A-containing
NMDARs, receptors that include NR2B inactivate more slowly and, consequently, have
been associated with increased levels of synaptic plasticity (Cull-Candy and Leszkiewicz,
2004; Lau and Zukin, 2007). Consistently, up-regulation of NR2B expression in mice
improves synaptic plasticity and memory formation (Crair and Malenka, 1995; Tang et al.,
1999). Numerous animal models that feature elevated NR2B levels via altered synthesis,
transport, or degradation exhibit improved synaptic plasticity and memory (Lee and Silva,
2009). Hence, targeting NR2B and its regulatory machinery has been singled out as an
attractive approach for cognitive enhancement (Bibb et al., 2010; Collingridge et al., 2013).
One possible strategy to increase NR2B levels involves induction of its de novo synthesis,
for example, via cAMP response element (CRE)-mediated gene expression or chromatin
remodeling (Fujita et al., 2012; Jiang et al., 2010; Myers et al., 1999). Alternative targets
include transport or degradation of NR2B via its coupling to distinct intracellular signaling
pathways (Hawasli et al., 2007; Yin et al., 2011). The molecular machinery regulating
trafficking, sub-cellular localization and degradation of NMDAR subunits is not yet well
understood, but it has been recognized that phosphorylation of NMDAR subunits including
NR2B is important for the regulation of such processes (Chen and Roche, 2007; Ma and Jan,
2002; Wenthold et al., 2003). One protein kinase implicated in the metabolism of NR2B is
Cdk5 (Cyclin-dependent kinase 5), albeit no direct phosphorylation of NR2B by Cdk5 has
been reported (Hawasli et al., 2007). Cdk5 is a proline-directed serine/threonine kinase that
is activated upon interaction with the neuron-specific co-factors p35 or p39 (Dhavan and
Tsai, 2001). Cdk5 has been implicated in numerous CNS processes, including cortical layer
formation, neurotransmission, and mnemonic functions (Angelo et al., 2006). Accordingly, a
previous study showed that Cdk5 conditional knockout (cKO) mice have improved synaptic
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plasticity and learning and memory via regulation of NR2B degradation by calpain (Hawasli
et al., 2007). Interestingly, transgenic mice overexpressing the truncated Cdk5 activator p25
also exhibit enhanced plasticity and memory formation (Angelo et al., 2006; Angelo et al.,
2003; Fischer et al., 2005), suggesting that reduced Cdk5 expression or displacement from
physiological substrates potentiates synaptic remodeling processes. Despite these results
indicating a close mechanistic relationship between NR2B and Cdk5 in the control of
mnemonic functions, the underlying molecular processes remain unknown.
Here we show that Cdk5 directly phosphorylates NR2B at Ser1116 and that the
phosphorylation state of this serine residue is specifically regulated by physiological
neuronal activity. Cdk5-dependent Ser1116 phosphorylation prevents cell surface expression
of NR2B-containing NMDAR and thus attenuates synaptic transmission. Disrupting the
Cdk5-mediated regulation of NR2B using small interfering peptides (siPs) to block protein-
protein interactions reduces this phosphorylation, increases NR2B surface levels, facilitates
neurotransmission, and improves hippocampus-dependent learning and memory, suggesting
that this novel regulatory mechanism may indeed be a suitable target for the development of
cognitive enhancers.
RESULTS
Cdk5 phosphorylates NR2B at Ser1116 and controls surface level expression
Cdk5 has been previously shown to contribute to synaptic plasticity and memory formation
through its control of NR2B (GluR2B) levels via calpain-mediated degradation (Hawasli et
al., 2007). As Cdk5 directly associates with this receptor, we investigated whether it could
phosphorylate NR2B. To identify novel Cdk5 phosphorylation sites, we employed a
PhosphoScan approach utilizing antibody-based enrichment of phospho-peptides from
mouse brain with a phospho-specific Cdk5 substrate antibody followed by tandem mass
spectrometry (Rush et al., 2005). This approach identified Ser1116 within the cytoplasmic
carboxy-terminal of NR2B as a novel Cdk5 phosphorylation site (Figure 1A and B). To
monitor physiological changes in Ser1116 NR2B phosphorylation, a phosphorylation state-
specific antibody was generated. The phospho-Ser1116 (P-S1116) NR2B antibody detected
time-dependent in vitro phosphorylation of recombinant NR2B at Ser1116 by Cdk5 (Figure
1C). Analysis of various mouse brain regions, namely cortex, hippocampus, cerebellum and
striatum, further revealed that NR2B is phosphorylated at Ser1116 in vivo (Figure S1A and
B), indicating that this NR2B phosphorylation functions broadly throughout the brain.
Treatment of acute mouse hippocampal slices with the specific Cdk5 inhibitor CP681301
caused dose-dependent P-S1116 NR2B reduction (Figure 1D). Moreover, Cdk5 inhibitor-
induced reduction of NR2B phosphorylation at Ser1116 followed a similar time-course as
the reduction of phospho-Thr75 DARPP-32, a well-established Cdk5 substrate (Bibb et al.,
1999) (Figure S1C). Finally, P-S1116 NR2B levels were markedly reduced in hippocampal
lysate of Cdk5 cKO mice (Hawasli et al., 2007) compared to wild type (WT) controls
(Figure 1E). Together, these results demonstrate that Ser1116 of NR2B is a physiological
Cdk5 phosphorylation site and raise the question of how this novel posttranslational
modification might affect NR2B function.
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NMDAR are assembled in the endoplasmic reticulum, trafficked along the secretory
pathway and delivered to the post-synaptic plasma membrane (Lau and Zukin, 2007;
Wenthold et al., 2003). The molecular machinery underlying NMDAR trafficking and sub-
cellular localization is not yet well characterized, but it has been recognized that
phosphorylation of NMDAR subunits including NR2B is important for the regulation of
such processes (Chen and Roche, 2007; Ma and Jan, 2002; Wenthold et al., 2003). We noted
that Ser1116 of NR2B occurs adjacent to a putative ER retention signal, RXR, (Ma and Jan,
2002) (i.e., NH2-…RRRPPRS*PDHK…COOH) and, therefore, investigated whether Cdk5-
dependent phosphorylation of NR2B at Ser1116 affected its subcellular localization. The
effect of Cdk5 inhibition on NR2B cell surface levels was assessed in cultured hippocampal
neurons overexpressing NR2B tagged with extracellular N-terminal green-fluorescent
protein (GFP-NR2B). Immunofluorescence staining using anti-GFP antibody thus enabled
visualization of cell surface GFP-NR2B. Surface-stained GFP-NR2B exhibited a punctate
pattern within dendritic processes (Figure 1F). Counter-labeling with Homer-1, a marker of
post-synaptic densities (PSDs), demonstrated that the cell surface fraction of GFP-NR2B
localized in proximity to PSDs. Treatment of cultured hippocampal neurons with the Cdk5
inhibitor CP681301 increased surface expression of NR2B in dendritic processes
approximately 1.3-fold (Figure 1F and G) suggesting that NR2B phosphorylation by Cdk5
modulates NR2B surface levels.
Cdk5-dependent regulation of NR2B function
The abundance of postsynaptic NMDAR is a major determinant of synaptic plasticity and
memory formation (Lee and Silva, 2009; Tang et al., 1999). Thus blocking Cdk5-dependent
retention of NR2B from the cell surface could be important in regulating its contribution to
NMDAR function. To assess this directly, mouse hippocampal brain slices were either
treated with CP681301 or vehicle (Figure 2A). Cdk5 inhibition increased cell surface
expression of NR2B 3.5-fold with concomitant reduction in P-S1116 levels to
approximately 30% of untreated controls. The effect appeared specific for NR2B as no
changes in surface levels of NR2A or the AMPA receptor subunit GluR1 were observed
(Figure S2A and B).
To evaluate the impact of Cdk5-dependent regulation of NR2B surface levels on
physiological function, whole-cell voltage-clamp recording of synaptically evoked
NMDAR-mediated excitatory postsynaptic currents (EPSC) were conducted in CA1
pyramidal neurons of hippocampal slices treated with the Cdk5 inhibitor CP681301 (Figure
2B–D). Administration of CP681301 increased the NMDAR-EPSC amplitude by
approximately 1.5-fold. Furthermore, application of the NR2B-specific inhibitor, ifenprodil,
had a greater attenuating effect on NMDAR-EPSC in CP681301-treated slices (33%
reduction) in comparison to controls (20% reduction) (Figure 2C), suggesting that the NR2B
component of NMDAR-EPSC was increased by Cdk5 inhibition. The deactivation kinetics
of NMDAR EPSC was increased in CP681301-treated slices (170.7 ± 19.4 ms) as compared
to untreated slices (112.1 ± 10.5 ms) (Figure 2D). This result is consistent with increased
NR2B function in response to CP681301 treatment, because NR2B-containing NMDAR
inactivate more slowly than receptors composed of other subunits (Cull-Candy and
Leszkiewicz, 2004).
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Together, these results indicate that Cdk5 regulates the subcellular localization of NMDAR
via NR2B phosphorylation at Ser1116, thereby controlling the level of functional NR2B-
containing NMDAR within the synaptic membrane and modulating NMDAR-mediated
synaptic currents.
Regulation of Phospho-Ser1116 NR2B by glutamatergic neurotransmission, synaptic
plasticity and memory formation
NMDAR are central to glutamatergic neurotransmission (Bliss and Collingridge, 1993) and
are controlled by complex molecular machinery integrating various postsynaptic signaling
cascades (Husi et al., 2000; Newpher and Ehlers, 2008). To better understand how Cdk5-
dependent NR2B phosphorylation might be regulated and contribute to NR2B function in
plasticity and memory formation, the effect of glutamatergic neurotransmission on P-S1116
NR2B was assessed ex vivo and in vivo. Treatment of acute mouse hippocampus slices with
NMDA dose-dependently attenuated P-S1116, when normalized to total NR2B levels
(Figure 3A). NMDA treatment also reduced total NR2B levels, consistent with previous
reports of NMDA-induced, calpain-mediated NR2B degradation (Guttmann et al., 2001;
Hawasli et al., 2007). The ability of NMDA to reduce P-S1116 in hippocampal slices was
attenuated by treatment with the PP2A/PP1 inhibitor okadaic acid (Figure S2C), indicating
that some of the NMDAR-induced effect on P-S1116 is mediated via serine/threonine
phosphatase activity.
In agreement with the attenuating effect of NMDA on P-S1116, induction of in vivo long-
term potentiation (LTP) in the hippocampal area CA1 also reduced P-S1116. Tetanic
stimulation of mouse Schaffer commissural-CA1 pyramidal cell synapses in vivo caused a
significant increase in fEPSP slope (1.4-fold as compared to baseline) that was maintained
for 1 h post-stimulus (Figure 3B). One hour after LTP induction, P-S1116 was reduced to
approximately 40% of the level in control CA1 lysates (Figure 3C), demonstrating the
physiological regulation of P-S1116 in synaptic plasticity. In contrast, induction of long-
term depression (LTD) did not affect P-S1116 levels (Figure 3D and E). As excitatory
activation of hippocampal NMDAR is integral to learning and memory (Nakazawa et al.,
2004), we also assessed the involvement of Cdk5-dependent NR2B phosphorylation in
mnemonic processes by evaluating P-S1116 levels following contextual fear conditioning.
One hour post-training, P-S1116 was reduced in CA1 lysates of fear-conditioned mice to
80% of the levels in non-shocked context-exposed controls (Figure 3F). Foot shock in the
absence of context had no effect on P-S1116. Taken together, these results show that NR2B
phosphorylation at Ser1116 is regulated by glutamatergic neurotransmission, synaptic
plasticity, and learning and memory, suggesting an important role for this signaling
mechanism in cognition.
The protein-protein interaction between NR2B and Cdk5 can be selectively disrupted by
small-interfering peptides
NR2B and Cdk5 form a complex both in vitro and in vivo (Hawasli et al., 2007). To identify
physiological protein-protein interaction sites between NR2B and Cdk5, overlapping eight
amino acid peptide cassettes of the NR2B carboxy-terminal domain were synthesized on a
peptide microarray microchip (Gao et al., 2004) that was then probed for Cdk5 binding
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using recombinant Cdk5 followed by immunodetection with anti-Cdk5 antibody (Figure
4A). Four motifs exhibiting high Cdk5-binding were identified by this approach (Figure
4B). To determine if these motifs were actual NR2B-Cdk5 interaction sites, peptides
corresponding to these motifs were synthesized and tested for their ability to interfere with
NR2B-Cdk5 binding. In this screen, the peptide corresponding to amino acid residues 1111–
1127 [RRPPRSPDHKRYFRDKE; NR2B small interfering peptide (NR2B siP)] most
potently blocked the pull-down of Cdk5 by recombinant GST-tagged NR2B in vitro (Figure
4C). Moreover, the NR2B siP dose-dependently inhibited in vitro phosphorylation of
Ser1116 NR2B by Cdk5 (Figure 4D). In contrast, a scrambled control peptide
(RRRSYFHKEDRPPRDK) did not attenuate Ser1116 phosphorylation in vitro.
Interestingly, the NR2B-siP did not inhibit the in vitro phosphorylation of inhibitor-1
(Figure S3A), a well-defined Cdk5 substrate (Nguyen et al., 2007), indicating that the
inhibition of Ser1116 NR2B phosphorylation by NR2B siP was specific.
To further assess the efficacy and consequences of targeting Cdk5-NR2B protein
interactions by small interfering peptides ex vivo and in vivo, cell-permeabilizing
polyarginine or penetratin N-terminal tags were included in the NR2B siP and control
peptides. These tags are commonly used to deliver peptides across the cell membrane into
the cytosol of neurons (Joliot and Prochiantz, 2004).
Consistent with the effects observed in vitro, application of the NR2B siP to hippocampal
slices decreased P-S1116 in a time- and dose-dependent manner (Figures 4E and S3B).
Treatment with the NR2B siP did not alter levels of NR2B or Cdk5 expression (Figures 4E
and S3B). The specificity of NR2B siP observed in vitro was retained in vivo, as it had no
effect on the phosphorylation state of the well-characterized Cdk5 site Thr75 DARPP-32
(Bibb et al., 1999), but it time-dependently reduced P-S1116 in acute mouse striatal slices
(Fig. S3C and D). These data show selective modulation of P-S1116 by siP, and also that
this mechanism may be targeted in multiple limbic structures mediating learning and
memory. Furthermore, NR2B siP treatment of hippocampal slices effectively blocked
subsequent co-immunoprecipitation of Cdk5 and NR2B (Figure 4F) indicating that siP
disrupts Cdk5-NR2B protein-protein interactions. In contrast, treatment with scrambled
control or the Cdk5 inhibitor CP681301, did not affect Cdk5-NR2B interactions.
Consistent with our data that Cdk5 regulates NR2B cell surface expression, the siP induced
a 3.3-fold increase in NR2B cell surface levels in hippocampal slices (Figure 4G). Finally,
cell surface GFP-NR2B levels increased 1.5-fold following 30 min treatment with NR2B siP
as compared to control peptide (S1116A) in primary hippocampal cultures (Figure 4H and
I). Thus, Cdk5-NR2B protein-protein interactions can be targeted in intact brain tissue with
NR2B siP, resulting in reduced Cdk5-dependent phosphorylation of Ser1116 NR2B and
appreciable increases in cell surface expression of the receptor.
Disruption of NR2B-Cdk5 interaction by NR2B siP increases NR2B function and facilitates
synaptic transmission
Given the efficacy of the NR2B siP in targeting Cdk5-NR2B interactions and increasing
NR2B cell surface levels, its impact on NMDAR-mediated EPSC was assessed. Treatment
of cortical slices with the NR2B siP produced a 1.8-fold increase in the NMDA/AMPA
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EPSC ratio as compared to a scrambled control peptide (Figure 5A). Moreover, slices
incubated with NR2B siP exhibited a 1.5-fold increase in the ifenprodil-sensitive NR2B
component of NMDAR EPSC (Figure 5B and C), suggesting that the NR2B siP-induced
increase in NMDAR EPSC is due to recruitment of additional NR2B-containing NMDAR to
the cell surface.
Given the importance of NR2B in mediating the potentiation of synaptic transmission during
plasticity, we assessed the effects of NR2B siP on extracellularly recorded field excitatory
postsynaptic potentials (fEPSP) in the hippocampal CA3-CA1 pathway. Treatment of
hippocampal slices with NR2B siP rapidly induced a 1.9-fold increase in fEPSP slope
compared to slices infused with a control peptide (Figure 5D and E). Upon washout of the
NR2B siP, fEPSP slopes progressively decreased until they reached steady-state levels with
fEPSP slopes that were 1.6-fold greater than control treated slices.
To determine whether the NR2B siP-induced changes in hippocampal neurotransmission
were due to NR2B, the effects of the NR2B siP on basal fEPSPs were assessed in slices co-
incubated with the specific NR2B antagonist Ro25–6981 (Figure 5F and G). Under these
conditions the NR2B siP-mediated increase was blocked. Cdk5 cKO mice lack
approximately 70% of hippocampal Cdk5 and exhibit a reduced threshold for induction of
long-term potentiation (LTP), but normal baselines for fEPSP fiber volley amplitude
(Hawasli et al., 2007). Interestingly, the ability of the NR2B siP to raise CA1-CA3 fEPSPs
was almost absent in Cdk5 cKO mice with a small (1.2-fold) but still significant increase in
fEPSP slopes (Figure 5F and G). Thus the effect of the peptide on synaptic transmission is
mediated via NR2B and Cdk5. Together these results show that NR2B siP selectively
disrupts NR2B-Cdk5 interaction, reduces P-S1116, increases cell surface levels of NR2B,
and facilitates neurotransmission by enhancing NR2B function.
NR2B siP improves learning and memory
The data presented so far indicate that the subcellular localization of NR2B is regulated by
Cdk5. Reduction in Cdk5 activity, as well as disruption of Cdk5-NR2B interactions
consistently increased NR2B surface levels and facilitated NMDA-mediated synaptic
function. As previous research has demonstrated that elevated NR2B function enhances
cognitive performance (Lee and Silva, 2009; Tang et al., 1999), we investigated whether
administration of NR2B siP can improve mnemonic function. For this purpose, we first
established robust in vivo protocols to deliver cell-penetrating NR2B siP to the appropriate
brain regions and test their effect on learning and memory. NMDAR are required for
hippocampus-dependent learning and memory, such as acquisition of contextual fear
memory (Barkus et al., 2010; Bast et al., 2003). Accordingly, infusion of the selective NR2B
inhibitors Ro25–6981 or ifenprodil into dorsal hippocampus was previously found to impair
contextual fear learning, but not locomotor or anxiety-related behavior (Zhang et al., 2008).
Hence, NR2B siP was infused bilaterally into the CA1 subfield of dorsal hippocampus
continuously for 72 h using mini-osmotic pumps. Due to the size of the osmotic pump and
the robust behavioral performance these initial experiments were performed in rat. Spatio-
temporal tracking of fluorescein-tagged NR2B siP (FITC siP) confirmed correct targeting,
continuity of the delivery, and neuronal uptake of the peptide. FITC siP was specifically
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detected in dorsal hippocampus at 12, 24, and 72 h after initiation of pumping. The FITC siP
was present in hippocampal area CA1 and labeled the cytoplasm of pyramidal neurons
(Figure 6A). After pumping was stopped, intracellular FITC siP signal was markedly
reduced by 6 h and had largely disappeared by 24 h (Figure S4A).
Within the FITC siP-infused region, P-S1116 was reduced by approximately 40% compared
to FITC-scrambled peptide infused controls (Figure 6B). Infusion of FITC siP also caused a
3-fold increase in NR2B surface expression (Figure 6C). Together, these results validate this
approach for the delivery of NR2B siP into pyramidal neurons of dorsal hippocampus and
show that the NR2B siP induces biochemical and cellular changes in vivo comparable to our
in vitro and ex vivo observations.
With these parameters established, the effect of NR2B siP infusion on fear memory was
evaluated. Continuous bilateral NR2B siP infusion into rat dorsal hippocampus 24 h prior to
fear conditioning increased hippocampus-dependent contextual fear memory 1.7-fold
compared to scrambled peptide controls (Figure 6D). In agreement with the hippocampal-
independent nature of cue-associated fear learning (Phillips and LeDoux, 1992), no effect
was observed on tone-induced freezing. Administration of neither NR2B siP, nor scrambled
control affected nociception, pain threshold, or motor reflexes (Figure S4B and C). During
extinction trials, contextual memory enhancement persisted in NR2B siP-treated rats at 48
and 72 h after initial training (Figure S4D and E). The conditioned fear response was
extinguished by 96 h for both groups (Figure S4E). Following extinction and expiration of
the mini-osmotic pump, rats were re-trained. Twenty-four hours after re-training, the
contextual fear memory was increased in rats previously infused with NR2B siP during the
initial acquisition phase, but not scrambled controls (Figure S4F) suggesting that behavioral
effects persist even after NR2B siP clearance. These data also indicate that the siP-improved
memory may have been more retained or consolidated.
The learning and memory improvements associated with NR2B siP infusion correlated
directly with reduced P-S1116 NR2B. NR2B siP infusion and fear conditioning, both
decreased P-S1116 NR2B in CA1 one hour post-training (Figure S5A). Animals that had
been infused with NR2B siP and undergone fear conditioning exhibited the lowest phosho-
Ser1116 levels.
Previous studies found that NMDAR inhibition during the acquisition phase impaired fear
memory (Bast et al., 2003; Zhang et al., 2008; Zhao et al., 2005). Therefore, we evaluated
whether an acute NR2B siP infusion shortly before the training session could also improve
fear memory. For this purpose, 3 month-old mice were acutely surgerized under isofluorane
anesthesia and NR2B siP was infused into dorsal hippocampus 90 min prior to fear
conditioning. Acute NR2B siP infusion resulted in significantly elevated freezing behavior
in the context test as compared to controls (Figure 6E). The freezing levels during the
context test of the acute paradigm were, in fact, comparable to the levels observed with
chronic infusion. The tone test did not reveal any significant changes between acute peptide-
infused groups. Finally, to evaluate whether NR2B siP administration may be a valid
treatment for age-related cognitive decline, 14 month-old mice were acutely infused with
NR2B siP and tested for fear memory (Figure S5B). As observed for 3 month-old mice,
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acute NR2B siP infusion 90 min prior to training increased contextual fear memory 1.7-fold
compared to control peptide or non-infused cannulated controls. Thus, increasing NR2B
surface levels may be a suitable memory enhancement strategy even for later stages in life.
These results are also consistent with studies showing that NR2B over-expression in
forebrain neurons improves learning and memory in aged mice (Brim et al., 2013; Cao et al.,
2007).
Taken together, these findings show that selective disruption of NR2B-Cdk5 interactions via
NR2B siP enhances hippocampus-dependent learning and memory through potentiation of a
regulatory mechanism that is involved in memory formation. Thus, it is possible that this
novel mechanism regulating NR2B function via Cdk5 may be a suitable target for the
development of memory enhancers as therapeutics for cognitive impairment as well as age-
dependent cognitive decline.
DISCUSSION
In this study, we present a novel molecular mechanism regulating the subcellular
localization of NR2B-containing NMDAR. This mechanism appears to be central to
synaptic transmission and mnemonic functions and can be targeted to enhance memory. A
model of this mechanism and the effects of targeting it may be suggested (Figure 6F). Upon
glutamatergic neurotransmission, such as that occurring during synaptic plasticity induction
or memory formation, Cdk5-dependent Ser1116 phosphorylation is reduced and
subsequently leads to increased cell surface levels of NR2B-containing NMDAR.
Consequently, selective disruption of NR2B-Cdk5 interactions via the NR2B siP increases
NR2B surface levels, thereby facilitating synaptic transmission. Intra-hippocampal infusion
of the NR2B siP improved fear memory suggesting that the regulation of NR2B by Cdk5
may be a suitable target for the development of cognitive enhancers.
The molecular basis of cognition is thought to involve activity-dependent changes in
intracellular signaling, gene expression, protein synthesis, remodeling of synapses and
neurotransmission (Bibb et al., 2010). In particular, excitatory glutamatergic
neurotransmission, as well as its regulatory machinery and downstream targets have been
singled out as central molecular mechanisms. Signaling cascades that modulate expression,
activity, trafficking, and degradation of neurotransmitter receptors are critical to the
formation of memories (Chen and Roche, 2007; Lau and Zukin, 2007; Wenthold et al.,
2003). Accordingly, enhanced synaptic plasticity, learning and memory has been observed
in several animal models that feature increased NR2B surface levels as a result of
manipulating various molecular processes including NR2B expression, trafficking, and
degradation (Crair and Malenka, 1995; Hawasli et al., 2007; Lee and Silva, 2009; Tang et
al., 1999; Wong et al., 2002; Yin et al., 2011). Thus a robust body of data singles out NR2B
as a prominent factor for cognitive function.
NR2B has been shown to serve as a substrate of various protein kinases (Wenthold et al.,
2003). In particular, tyrosine phosphorylation of its extreme C-terminus modulates its
anchoring to the postsynaptic density and may prevent endocytosis. Furthermore, NR2B has
been suggested to traffic dynamically from extra- to intra-synaptic locations on the cell
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surface, possibly through association of its extreme C-terminus with different members of
the membrane-associated guanylate kinase (MAGUK) family. In contrast, Ser1116 appears
to reside within a region of the cytoplasmic terminus that interacts with early components of
receptor trafficking in the postsynaptic endoplasmic reticulum (Vandenberghe and Bredt,
2004).
Previously Cdk5 cKO was shown to increase total NR2B levels by disrupting the NR2B-
Cdk5-calpain complex, thereby attenuating activity-dependent degradation of NR2B by
calpain (Hawasli et al., 2007). Here, pharmacological inhibition of Cdk5 revealed that the
protein kinase also phosphorylates NR2B, thereby modulating the activity-dependent
trafficking of the receptor to the cell surface. Thus Cdk5 appears to have two roles,
regulating NR2B trafficking as well as metabolism. Both these roles are likely important for
synaptic plasticity and memory, although the temporal sequence and molecular integration
of these two activity-dependent events requires further study.
It also remains to be determined if dephosphorylation of Ser1116 targets NR2B selectively
to the synapse or to both synaptic and extrasynaptic compartments. As the increases in cell
surface NR2B observed here were greater than the potentiation of NR2B-mediated current,
it is possible that not all NR2B driven to the surface was functional. Interestingly, other
NMDAR subunits possess endoplasmic reticulum retention motifs similar to the one
indicated here in NR2B. Furthermore, some of these are also regulated via phosphorylation
(Scott et al., 2001) and in response to neuronal activity (Mu et al., 2003), suggesting a
common overall process in synaptic remodeling or homeostasis.
Numerous neurodevelopmental, neurological, and neuropsychiatric disorders, such as
Alzheimer’s disease, depression, and schizophrenia manifest cognitive deficits.
Interestingly, deficiencies in NMDAR trafficking have been implicated in the
pathophysiology of many of these diseases [e.g., see (Snyder et al., 2005)]. Moreover, age-
related cognitive decline occurs progressively in all aging humans, albeit at variable rates.
While behavioral interventions are being advanced as one group of approaches, effective
treatments to counter cognitive deficits or memory decline are extremely limited.
Peptides are now an integral component of CNS research, and protein-protein interactions
and intracellular signaling mechanisms provide a very large base of new therapeutic targets
(Jubb et al., 2012). Until recently, CNS drug discovery has focused on developing synthetic
small molecules that act primarily upon targets involved in neurotransmission including
receptors and ion channels. Drug target pool algorithms such as the “rule of five” (Lipinski,
2000) and “the druggable genome” (Hopkins and Groom, 2002) have been used in an effort
to facilitate the discovery of small molecules of high specificity for oral delivery. However,
these restrictions have often had the unintended consequences of producing molecules with
poor selectivity and unwanted side effects. Larger molecules including peptides and
peptidomemetics that interfere with protein-protein interactions provide more contact with
targets and greater selectivity but have been limited by low bioavailability, poor membrane
permeability, and metabolic instability. These obstacles are being circumvented by a number
of creative means and protein- or peptide-based drugs are now roughly 10% of the
pharmaceutical market and growing (Craik et al., 2013). As an example of this potential,
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peptides that target NR2B interactions with the postsynaptic density have been shown to
neuroprotect from ischemic injury in primates (Cook et al., 2012).
Here we demonstrate memory enhancement by selectively targeting a single
phosphorylation site and NR2B-Cdk5 protein-protein interactions with a peptide injected
intracranially. It will be interesting to find out, if further optimization in the targeting of this
and other synaptic mechanisms will lead to more practical delivery modes and clinically
applicable therapies.
EXPERIMENTAL PROCEDURES
Please see the Supplemental Experimental Procedures for detailed methods on
Phosphorylation-site Identification, Phosphorylation State-specific Antibody Generation, In
vitro Phosphorylation, Binding Assays, Peptide Array Analysis, In vivo LTP, Whole-cell
Recordings, Hippocampal cannulation and siP infusion
Antibodies and Reagents
Cdk5 (C-8), and NR2A antibodies (Ab) were obtained from Santa Cruz; P-Thr75
DARPP-32, DARPP-32, and Inhibitor-1 Ab from Cell Signaling Technology; EGFP, FITC
and α-tubulin Ab from Abcam; NR2B Ab from PhosphoSolutions; Homer-1 Ab from
Synaptic System; MAP-2 and NeuN Ab from Millipore; Secondary anti-mouse, anti-rabbit
and anti-goat IgG Ab from Pierce; Cy3-conjugated anti-rabbit IgG secondary Ab from
Jackson Immunoresearch; and Alexa647-conjugated anti-mouse IgG secondary Ab from
Molecular Probes. P-Ser6 inhibitor-1 Ab was previously described (Nguyen et al., 2007).
The specific Cdk5 inhibitor, CP681301, was provided by Pfizer Pharmaceutical. Ifenprodil
and Ro 25–6981 were from Tocris. All peptides were synthesized by the UT Southwestern
Protein Chemistry Technology Center utilizing the Perseptive Biosystems Pioneer and
Applied Biosystems 433 synthesizers. Peptides were verified by mass spectrometry analysis
and reversed-phase HPLC chromatography. The sequences of the small interfering peptides
(siP) were NR2B siP, RRPPRSPDHKRYFRDKE; scrambled, RRRSYFHKEDRPPRDK;
R7 NR2B siP, RRRRRRRRPPRSPDHKRYFRDKE; R7 scramble,
RRRRRRRRRSYFHKEDRPPRDK; Pen NR2B siP, RQIKIWFQNRRMKWKK-
PPRSPDHKRYFRDKE and Pen control, RQIKIWFQNRRMKWKK-
PPRAPDHKRYFRDKE. The FITC tag was attached at the C-terminus of the siP.
Animals
Animals were housed in a 12 h light/dark cycle (lights on from 6:00 a.m. to 6:00 p.m.), with
food and water available ad libitum. Mice in the C57/BL6 background were obtained from
Jackson and were housed 3–4 per cage. Cdk5 cKO mice were bred and maintained as
previously specified (Hawasli et al., 2007). For all experiments, aged-matched male
littermates were used, unless otherwise noted. Sprague-Dawley rats were obtained from
Charles River Laboratories and bred and maintained at the UT Southwestern animal facility.
All behavioral experiments were conducted in the UTSW Rodent Behavior Core. All
experimental procedures were reviewed and approved by the University of Texas
Southwestern Institutional Animal Care and Use Committee (IACUC).
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Slice Pharmacology, Immunoprecipitation and Cell Surface Labeling
Hippocampal, striatal and cortical slices were prepared as previously described (Hawasli et
al., 2007; Sahin et al., 2006; Yuen et al., 2012). Pharmacological treatments were performed
in Mg2+-free Kreb’s buffer containing NMDA (50 or 100 μM, 15 min), CP-681301 (5–100
μM, 60 min) or siP (0–100 μM, 0–180 min). The R7-tagged peptides were used in slice
experiments assessing substrate phosphorylation levels. Cell surface biotinylation assays
were performed using Pierce® Cell Surface Protein Isolation Kit (Thermo Scientific)
according to manufacturer’s instruction. In brief, hippocampal slices were equilibrated in
ice-cold oxygenated ACSF for 5 min and then incubated for 30 min with Sulfo-NHS-SS-
Biotin (0.5 mg/ml in ACSF; Pierce). Biotinylation reaction was quenched with ACSF
containing 50mM NH4Cl and 50mM glycine and tissue dissected in ice-cold dissection
buffer containing protease and phosphatase inhibitors (Plattner et al., 2006).
Immunoprecipitation (IP) was performed as previously described (Plattner et al., 2006).
Lysate Preparation and Immunoblotting
Brain dissection, tissue removal and lysate preparation were performed with specific
emphasis on maintaining protein integrity and phosphorylation levels by using protease and
phosphatase inhibitors as described (Bibb et al., 1999; Plattner et al., 2006). Graphs of all
quantitative immunoblot analyses of P-S1116 NR2B represent the ratio of P-S1116/Total
NR2B. Hippocampal subfield CA1 tissue including stratum radiatum, stratum pyramidale
and stratum oriens was microdissected in ice-cold dissection buffer containing protease and
phosphatase inhibitors (Plattner et al., 2006) using a dissecting microscope. After excision of
the intact hippocampus from the brain, the dentate gyrus and CA3 were removed
longitudinally using the basal vein and the hippocampal fissure as guidance clues.
Extracellular Field Recordings
Hippocampal slices were prepared from 3 month-old C57BL/6 mice as described (Hawasli
et al., 2007) and field excitatory postsynaptic potentials (fEPSP) from CA1 were evoked by
square current pulses (0.1 ms at 0.033 Hz) with a bipolar stimulation electrode placed at the
Schaffer collaterals. Results were obtained using a stimulus intensity to induce 50% of the
maximal fEPSP slope. Once the baseline was stable, Pen siP or Pen control peptides were
added to the perfusion buffer for 30 min. For recordings performed in presence of the NR2B
selective blocker Ro 25–6981, the Pen siP peptide was added 10 min after starting Ro 25–
6981 (3 μM) bath perfusion. The effects of the siPs were evaluated as percent change from
baseline fEPSP slope.
LTD analysis was performed in hippocampal slices from 16–17 day-old C57BL/6 mice as
previously reported (Billard, 2010; Milner et al., 2004) using modified ACSF (in mM: 130
NaCl, 26 NaHCO3, 3 KCl, 2 MgCl2, 1.25 NaH2PO4, 1 CaCl2, 10 Glucose, pH 7.4, 300
mOsm). After 15 minutes of stable baseline recording a low frequency stimulation protocol
(900 stimuli at 1 Hz) was applied to induce LTD that was maintained for at least one hour.
At the end of the LTD recording the CA1 was micro-dissected and homogenized in lysate
buffer containing protease and phosphatase inhibitors.
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Dissociated neuronal cultures, transfection, drug treatments and live-labeling of cell
surface receptors
Dissociated hippocampal neurons were prepared from P0 rats as described in (Goda and
Colicos, 2006) and plated onto glass coverslips coated with poly-D-lysine (10 μg/ml) and
laminin (2 μg/ml). Cultures were maintained in Neurobasal media (Invitrogen)
supplemented with 6 mg/ml glucose, 0.1% Mito™ serum extender, 2.5% B27, and 2 mM
Glutamax. Hippocampal neurons were transfected at DIV 7–8 using the calcium-phosphate
method and used at DIV 14–18. Constructs include pRK5-EGFP-NR2B that encodes a N-
terminally EGFP-tagged NR2B subunit (GFP-NR2B).
To evaluate the effect of Cdk5 inhibition on cell surface expression of NR2B, neuronal
cultures were treated with 25 μM CP68130 for 1 h or with 2 μM NR2B-siP for 30 min, 6–10
days after transfection with pRK5-EGFP-NR2B. DMSO or control peptides were used as
controls. Immunofluorescence staining of cell surface GFP-NR2B was performed by
incubating non-permeabilized, live neuronal cultures with rabbit polyclonal EGFP ab
(1:500, Abcam, Ab6556) for 15 min at 37°C (Cingolani et al., 2008; Pozo et al., 2012).
Neurons were fixed in PBS containing 4% paraformaldehyde and 4% sucrose for 10 min at
25°C and then permeabilized and blocked with PBS containing 10% fetal bovine serum,
0.2% gelatine and 0.02% Triton X-100 for 1h at 25°C. Following incubation with mouse
monoclonal Homer-1 ab (1:1000, SYSY, 160011) for 1h at 25°C, neurons were washed and
incubated with Cy3-conjugated anti-rabbit IgG and Alexa 647-conjugated anti-mouse IgG
for 1h at 25°C. Cells were washed and mounted onto microscope slides for confocal
imaging. Z-stacks were acquired with an inverted 510 Meta Zeiss confocal microscope using
a 63X water objective, sequential mode and 4 frames average. Baseline microscopy settings
were established using control cultures and maintained constant throughout the entire
imaging session. ImageJ was used to project Z-stacks and measure dendritic fluorescence.
Dendritic length was assessed by tracing processes with NeuronJ and used to normalize
dendritic fluorescence.
Animal Behavior
All behavior was carried out with the experimenter blind to treatment groups. For cued fear
conditioning in rats, animals were left to explore the conditioning box (Med Associates) for
2 min, followed by a 30 s period with tone representation (90 dB, 10 kHz), which co-
terminated with a mild foot shock (2 s, 0.7 mA, constant current). Rats remained in the
chamber 2 min after shocking before returning to their home cage. Conditioning boxes were
thoroughly cleaned after each animal. To test context-dependent fear memory, rats were re-
introduced 24 h post-shock into the conditioning box for 5 min. Freezing responses
(motionless except respirations) were recorded using a 5-s interval time-sampling method.
Twenty-seven hours after conditioning, tone-recall was assessed in a novel context with
novel odor (vanilla). The rats were left exploring the novel context for 3 min without tone
followed by a 3 min period with tone representation. Extinction of fear memory was
evaluated by re-exposing rats to the conditioning box at 24, 48, 72, and 96 h post-shock for
5 min. Following fear memory extinction, rats were re-trained with a 0.7 mA foot shock and
contextual learning was analyzed 24 h after re-training. Nociceptive response and motor
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reflex were evaluated by measuring the stimulus threshold to elicit flinching, jumping, and
vocalizing in the fear conditioning paradigm and tail flick test.
For mice, cued fear conditioning was conducted in an automated system (Med Associates)
using a two conditioned stimulus (CS)–unconditioned stimulus (US) pairings paradigm of 4
min with 60 s inter-trial-interval. The CS was a tone (75 dB, 8 kHz) coterminating with a
mild foot shock US (2 s, 0.7 mA, constant current). Context-dependent conditioning was
tested 24 h later by exposing the mice to the conditioning box for 5 min and tone-dependent
freezing was measured at 27 h by placing the mice in a novel context with novel scent
(vanilla) for 3 min pre-CS followed by 3 min CS. Freezing responses were assessed by
computer-aided scoring, as well as, offline manual scoring. For biochemistry and cell
surface biotinylation animals were sacrificed 1 h after fear conditioning.
Statistical analyses
All data are represented as mean ± SEM unless stated otherwise. Statistical analysis was
performed using the Student t-test unless stated otherwise. For all experiments *p < 0.05;
**p < 0.01; ***p < 0.001 were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• The NR2B subunit of the NMDA receptor is phosphorylated at Ser1116 by
Cdk5.
• Synaptic plasticity and memory formation alter NR2B Ser1116 phosphorylation.
• Disruption of NR2B-Cdk5 complex increases surface NR2B and synaptic
transmission.
• Hippocampal infusion of NR2B-Cdk5 small interfering peptide improves
memory.
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Figure 1. Cdk5 phosphorylates the NR2B subunit of the NMDAR at Ser1116 and regulates its cell surface expression
(A) Schematic of NR2B indicating domains and motifs. (B) Positive identification of serine residue 1116 of NR2B as a Cdk5
substrate by LC MS/MS analysis of phosphopeptides immunoprecipitated with phospho-Cdk substrate antibody. (C) Time-
dependent Ser1116 NR2B phosphorylation (P-S1116) by Cdk5 in vitro detected by quantitative immunoblottng. Quantitated
values were normalized to total NR2B levels. (D) Dose-dependent reduction of P-S1116 in hippocampal slices incubated with
the Cdk5 inhibitor, CP681301 (n = 4; *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA). (E) Quantitative immunoblot analysis of
P-S1116 and total NR2B in hippocampal lysates from Cdk5 cKO and WT mice (n = 4). Loss of Cdk5 in cKO is also shown
(bottom panel). (F) Inhibition of Cdk5 increases NR2B cell surface levels in hippocampal neurons. Top panels show
immunofluorescence staining of cell surface GFP-NR2B (green) and post-synaptic, intra-neuronal Homer-1 (red) in
hippocampal neurons treated with vehicle (control) or the Cdk5 inhibitor CP681301. Bottom panels depict high magnification of
stained dendrites. (G) Quantification of cell surface GFP-NR2B fluorescence within dendritic processes (n = 22–26 cells). Data
are represented as mean ± SEM. See also Figure S1.
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Figure 2. NR2B phosphorylation at Ser1116 regulates NMDAR function
(A) Increased cell surface NR2B correlates with reduced P-S1116 in hippocampal slices. Levels of cell surface-biotinylated
NR2B pulled-down from lysates of hippocampal slices incubated in the absence (−) or presence (+) of the Cdk5 inhibitor
CP681301 are shown with blots and quantitation (n = 4). Prior to pull-down, lysates were tested for NR2B Load and P-S1116
(bottom panel). (B) Effect of Cdk5 inhibition on the NR2B component of NMDAR-EPSC. Voltage-clamp EPSC recordings of
total NMDAR-EPSC (INMDA) in the absence or presence of the specific NR2B inhibitor ifenprodil from pyramidal neurons
within the hippocampal area CA1 pretreated with vehicle (control) or the Cdk5 inhibitor CP681301 are shown. (C and D)
Quantitation of NMDAR EPSC recordings showing an increase of ifenprodil-sensitive NR2B component (C) and prolonged
decay kinetics (D) of NMDAR EPSC in cells incubated in the absence (−) or presence (+) of CP681301 (n = 6–7). Data are
represented as mean ± SEM. See also Figure S2A and B.
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Figure 3. Phosphorylation of Ser1116 NR2B is modulated by glutamatergic neurotransmission, synaptic plasticity, and memory
formation
(A) Immunoblots of lysates from NMDA-treated mouse hippocampal slices probed for P-S1116 and total NR2B (n = 4; *p <
0.05; ANOVA). (B) Induction of in vivo CA1 LTP in mouse. Sample traces of 5 min periods pre- (a) and post- (b) high
frequency stimulation (HFS; two trains of 50 pulses at 100 Hz; 30 s inter-train interval) and LTP induction are shown. (C)
Quantitative immunoblotting of CA1-specific lysates from non-induced (−) and LTP-induced (+) mice for P-S1116 and total
NR2B (n = 5). (D) Induction of CA1 LTD in mouse hippocampal slices with sample traces of 5 min periods pre- (a) and post-
(b) low frequency stimulation (LFS; 900 stimuli at 1 Hz). (E) Quantitative immunoblotting of non-induced (−) and LTD-
induced (+) CA1-specific lysates probed for P-S1116 and total NR2B (n = 5). (F) Quantitative immunoblots of CA1-specific
lysates from contextual fear conditioned (FC) and control (Context and Foot Shock) mice obtained 1 h post-training for P-S1116
and total NR2B levels (n = 4–6). Data are represented as mean ± SEM. See also Figure S2C.
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Figure 4. Identification of NR2B-Cdk5 interaction motifs and development of a small-interfering peptide (siP)
(A) Peptide micro-array of the NR2B C-terminal domain showing high (+, red) to low (−, blue) Cdk5 binding regions. (B) The
cytoplasmic C-terminus amino acid sequence of NR2B with potential Cdk5 binding sites highlighted with their corresponding
peptide array tiles. (C) NR2B siP blocks pull-down of Cdk5 with recombinant NR2B immobilized on GST beads, demonstrating
disruption of NR2B-Cdk5 interaction in vitro. Immunoblots show relative levels of NR2B and Cdk5 under conditions indicated.
NR2B siP dose-dependently disrupts NR2B-Cdk5 binding in vitro as depicted in plot (n = 3). (D) Immunoblots showing that
NR2B siP dose-dependently inhibits in vitro phosphorylation of Ser1116 NR2B by Cdk5, whereas the control peptide
(scramble) has no effect.
(E) Time-dependent reduction of P-S1116 in hippocampal slices treated with NR2B siP (25 μM) or the Cdk5 inhibitor
CP681301 (CP; 50 μM), but not scrambled (Scr) control peptide (n = 4; *p < 0.05, **p < 0.01; ANOVA). (F) NR2B siP, but not
the scrambled peptide, nor CP681301 (CP) disrupts NR2B-Cdk5 interaction in hippocampal slices (4 pooled slices for each
sample) as evaluated by co-immunoprecipitation. Cdk5 Load is also shown. (G) NR2B cell surface levels are increased in
hippocampal slices treated with NR2B siP (1 h, 100 μM) or the Cdk5 inhibitor CP681301 (1 h, 50 μM), but not with control
peptide (Scramble; 1 h, 100 μM) (n = 4; **p < 0.01; ***p < 0.001; ANOVA). NR2B Load is also indicated. (H)
Immunofluorescence staining of cultured hippocampal neurons for surface GFP-NR2B after treatment with control peptide or
NR2B-siP. (I) Quantification of dendritic cell surface GFP-NR2B (n = 49–64 cells). Scale bar = 20 μm. Data are represented as
mean ± SEM. See also Figure S3.
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Figure 5. Disruption of NR2B-Cdk5 interaction by NR2B-siP facilitates synaptic transmission
(A) Recordings and quantification of NMDAR/AMPAR EPSC ratio from cortical pyramidal neurons treated with NR2B siP or
scrambled (Scr) control (n = 12–16). (B and C) NMDAR EPSC sensitivity to the NR2B inhibitor, ifenprodil, in slices incubated
with NR2B siP or scramble control (n = 6–7). (D and E) Extracellular CA3-CA1 field recordings in hippocampal slices treated
with NR2B siP or control peptide (30 min, 2 μM). Sample traces of 2 min before (a) and at end (b) of siP application and
Quantitation of fEPSP slope (n = 4). (F and G) Extracellular field recordings in hippocampal slices incubated with the specific
NR2B inhibitor Ro 25–6981 (3 μM) or from Cdk5 cKO were treated with NR2B siP (30 min, 2 μM) and quantification of fEPSP
slope (n = 3) did not show a significant effect of NR2B siP with NR2B inhibition or in absence of Cdk5 (cKO). Data are
represented as mean ± SEM.
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Figure 6. Enhancement of fear memory by NR2B siP
(A) Immunostain of rat dorsal hippocampus infused for 24 h with FITC NR2B siP (green) and counterstained with MAP2 (red).
Inset shows FITC-positive CA1 pyramidal neurons. Scale bars = 250 μm and 50 μm (inset). (B and C) Immunoblots showing
infused NR2B siP vs. scramble control reduces P-S1116 (n = 4) (B) and increases NR2B cell surface expression (4 pooled tissue
punches for each condition) (C) in epifluorescent hippocampal area CA1. (D) Experimental design and quantitation of context-
and tone-elicited fear memory in two-month-old rats chronically infused with scrambled or NR2B siP into dorsal hippocampus
(n = 20) showing that NR2B siP improved contextual fear memory. (E) Experimental design and quantitation of fear memory in
acutely infused three-month-old mice. Ninety minutes prior to training mice were acutely infused with NR2B siP or control
peptide into dorsal hippocampus. Twenty-four hours later, NR2B siP treated mice exhibited improved context freezing, but not
freezing to tone (n = 6–10). Data are represented as mean ± SEM. See also Figure S4 and S5.
(F) Model of NR2B regulation via Ser1116 phosphorylation by Cdk5. At basal state, Cdk5 constitutively phosphorylates NR2B
at Ser1116, withholding it from the cell surface. Glutamatergic neurotransmission reduces Cdk5-dependent NR2B
phosphorylation enabling translocation of NR2B to the cell surface and thereby contributing to memory formation. Addition of
NR2B siP disrupts NR2B-Cdk5 interactions, reduces Ser1116 phosphorylation, and more NR2B translocates to the cell surface,
thereby enhancing memory formation.
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